Embryo editing companies Bootstrap Bio, Manhattan Genomics shut down

Two companies, Bootstrap Bio and Manhattan Genomics, that were focused on using gene editing technologies to prevent serious diseases in human embryos have ceased operations. The closure of these ventures highlights the significant challenges and potential turmoil within the burgeoning field of 'designer baby' technology. While the exact reasons for their shutdowns were not detailed, the difficulties in navigating the complex ethical, regulatory, and scientific landscape of human germline editing likely played a substantial role. This development raises questions about the future viability and public acceptance of such advanced biotechnologies.